Viatris Stock-Based Compensation 2010-2025 | VTRS

Viatris annual/quarterly stock-based compensation history and growth rate from 2010 to 2025. Stock-based compensation can be defined as the estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors
  • Viatris stock-based compensation for the quarter ending March 31, 2025 was $0.055B, a 18.2% increase year-over-year.
  • Viatris stock-based compensation for the twelve months ending March 31, 2025 was $0.397B, a 8.66% decline year-over-year.
  • Viatris annual stock-based compensation for 2024 was $0.146B, a 19.15% decline from 2023.
  • Viatris annual stock-based compensation for 2023 was $0.181B, a 55.24% increase from 2022.
  • Viatris annual stock-based compensation for 2022 was $0.116B, a 4.68% increase from 2021.
Viatris Annual Stock-Based Compensation
(Millions of US $)
2024 $146
2023 $181
2022 $116
2021 $111
2020 $79
2019 $57
2018 $-3
2017 $75
2016 $89
2015 $93
2014 $66
2013 $47
2012 $43
2011 $43
2010 $31
2009 $31
Sector Industry Market Cap Revenue
Medical Medical Services $10.962B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $144.923B 27.18
CVS Health (CVS) United States $84.250B 10.47
Elevance Health (ELV) United States $79.134B 10.21
Cencora (COR) United States $56.436B 19.63
DiDi Global (DIDIY) China $22.826B 24.25
Natera (NTRA) United States $22.062B 0.00
Labcorp Holdings (LH) United States $21.762B 17.65
BioMerieux (BMXMF) France $16.861B 0.00
EUROFINS SCIENT (ERFSF) Luxembourg $13.704B 0.00
Solventum (SOLV) United States $13.538B 14.33
CochLear (CHEOY) Australia $12.960B 0.00
ICON (ICLR) Ireland $12.180B 11.32
Revvity (RVTY) United States $11.893B 20.47
Avantor (AVTR) United States $9.465B 13.75
Medpace Holdings (MEDP) United States $9.371B 24.89
HealthEquity (HQY) United States $8.758B 38.36
Sonic Healthcare (SKHHY) Australia $8.535B 0.00
Charles River Laboratories (CRL) United States $7.735B 15.16
Caris Life Sciences,�Inc (CAI) United States $6.798B 0.00
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.867B 28.67
BrightSpring Health Services (BTSG) United States $3.868B 35.48
Sotera Health (SHC) United States $3.304B 18.77
Surgery Partners (SGRY) United States $2.822B 36.70
Alignment Healthcare (ALHC) United States $2.693B 0.00
Concentras Parent (CON) United States $2.647B 15.30
Organon (OGN) United States $2.639B 2.80
GeneDx Holdings (WGS) United States $2.562B 98.67
PACS (PACS) United States $1.987B 0.00
Ardent Health (ARDT) United States $1.920B 8.18
Progyny (PGNY) United States $1.821B 40.08
GoodRx Holdings (GDRX) United States $1.805B 36.11
Premier (PINC) United States $1.789B 13.58
Teladoc Health (TDOC) United States $1.465B 0.00
Establishment Labs Holdings (ESTA) $1.283B 0.00
Pediatrix Medical (MD) United States $1.184B 9.01
CareDx (CDNA) United States $1.085B 16.95
Agilon Health (AGL) United States $0.989B 0.00
Ryman Healthcare (RYHTY) New Zealand $0.919B 0.00
AMN Healthcare Services Inc (AMN) United States $0.843B 7.89
QDM (QDMI) Hong Kong, SAR China $0.729B 0.00
Nutex Health (NUTX) United States $0.679B 10.28
Embecta (EMBC) United States $0.599B 4.04
LifeMD (LFMD) United States $0.588B 0.00
InnovAge Holding (INNV) United States $0.560B 0.00
Sonida Senior Living (SNDA) United States $0.470B 0.00
Auna S.A (AUNA) Luxembourg $0.467B 10.52
Omada Health (OMDA) $0.466B 0.00
SBC Medicals (SBC) United States $0.463B 0.00
Enhabit (EHAB) United States $0.390B 32.12
So-Young (SY) China $0.338B 0.00
Performant Healthcare (PHLT) United States $0.326B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.316B 0.00
Beauty Health (SKIN) United States $0.266B 0.00
Oncology Institute (TOI) United States $0.218B 0.00
DocGo (DCGO) United States $0.160B 26.17
Pheton Holdings (PTHL) China $0.121B 0.00
Sera Prognostics (SERA) United States $0.092B 0.00
KindlyMD (NAKA) United States $0.079B 0.00
Ascend Wellness Holdings (AAWH) United States $0.070B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.056B 0.00
ModivCare (MODV) United States $0.045B 0.00
Biodesix (BDSX) United States $0.040B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.034B 0.00
Basel Medical Group (BMGL) Singapore $0.032B 0.00
OSR Holdings (OSRH) United States $0.027B 0.00
Intelligent Bio Solutions (INBS) United States $0.013B 0.00
BioNexus Gene Lab (BGLC) $0.012B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
SeaStar Medical Holding (ICU) United States $0.006B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00